secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0000944809-22-000041
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Health Q2 net loss of $101.7M on $309.9M revenue; NGENLA launch, ModeX acquisition
--------------------------------------------------------------------------------

- Acquired ModeX for $300M in stock; Dr. Zerhouni appointed President/Vice Chairman, Dr. Nabel Chief Innovation Officer.
- Pfizer launched NGENLA in Europe/Japan; OPKO received $85M milestone payment.
- Closed GeneDx sale to Sema4 for ~$322M upfront (cash + shares) plus up to $150M milestones.
- BRL diagnostics revenue fell to $186.8M from $397.2M; COVID PCR tests dropped to 0.9M from 2.8M.
- Net loss includes $71.2M non-cash charge from Sema4 stock decline; operating loss of $10.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000094480922000041/0000944809-22-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000094480922000041/opk-20220804.htm
  HTML page:      https://secwatch.observer/filing/0000944809-22-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer